{"id":"W4236936284","doi":"10.1093/ecco-jcc/jjw019.021","title":"OP022. Efficacy and safety of oral tofacitinib for induction therapy in patients with moderate-to-severe Crohn’s disease: results of a Phase 2b randomised placebo-controlled trial","year":2016,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Robarts Clinical Trials; University of Calgary","funders":"","keywords":"Tofacitinib; Medicine; Crohn's disease; Placebo; Randomized controlled trial; Internal medicine; Induction therapy; Disease; Gastroenterology; Alternative medicine; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002814458,0.001481174,0.002453956,0.0003605144,0.0003334669,0.001235307,0.0009321439,0.002306946,0.00997751],"category_scores_gemma":[0.001985305,0.0005529096,0.001654793,0.000446409,0.0009553578,0.0009787127,0.0003437859,0.003140532,0.001641372],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006233536,"about_ca_system_score_gemma":0.001166073,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004193562,"about_ca_topic_score_gemma":0.0008716452,"domain_scores_codex":[0.999223,0.0004457094,0.00005362065,0.00009874214,0.00007035789,0.0001086049],"domain_scores_gemma":[0.998821,0.0003652103,0.0002815712,0.00007874032,0.0000760273,0.0003773826],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9722072,0.004786715,0.0005294607,0.001007549,0.0004805822,0.00006363278,0.0000385135,0.000115017,0.002858552,0.00007541016,0.001026944,0.0168103],"study_design_scores_gemma":[0.965963,0.03192857,0.00111988,0.00002902942,0.0001610894,0.0000304701,0.000006697869,0.0001054537,0.0001867049,0.00004580635,0.0004176503,0.000005777339],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.965126,0.01529821,0.0007981934,0.002217163,0.0008399713,0.006623244,0.002699494,0.0002402999,0.00615735],"genre_scores_gemma":[0.9767025,0.004696094,0.001655028,0.002304441,0.001035862,0.006398066,0.002627915,0.00003424861,0.004545784],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00997751,"threshold_uncertainty_score":0.03337812,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009387981790265398,"score_gpt":0.2574140732326831,"score_spread":0.2480260914424177,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}